Introduction {#S0001}
============

Cancers have currently become a severe health threat all over the world.[@CIT0001] There has been tremendous progress in the treatment of cancer including chemotherapy, radiation therapy, immunotherapy, photodynamic therapy (PDT) and photothermal therapy. Chemotherapy remains the most common therapeutic modality due to its high efficiency.[@CIT0002] PTT is also a highly effective intervention to ablate tumor tissues in a noninvasive and harmless manner.[@CIT0003] However, these types of single modal therapy have a limited effectiveness of completely tumor eradication without any recurrence.[@CIT0004] Thus, combination therapy with different therapeutic agents and anticancer mechanisms has been developed as a more preferable therapeutic modality. Taking advantage of each modality, combination therapy may suppress tumor growth cooperatively.[@CIT0005]--[@CIT0009] And "chemotherapy + PTT" has been explored as a promising modality to augment tumor treatment.[@CIT0010]--[@CIT0012]

As we all know, chemotherapy suffer from major limitations. Its toxic side effects damage normal tissues, and another challenge is that chemotherapeutic agents could induce MDR in tumors after prolonged treatments. One well investigated mechanism of MDR is the over-expression of efflux pumps on the cell surfaces, such as, the ABC-transporter family P-gp. P-gp, which is also called drug pump, is expressed in various of tumors. It transports drugs out of the cells,[@CIT0011] hence reducing the intracellular accumulation of chemotherapeutic agents. Several inhibitors and modulators of P-gp have been developed to co-delivery with anticancer drugs to achieve the aim of reversing MDR, but their use have been limited to high toxicity and unfavorable pharmacokinetic interactions.[@CIT0013],[@CIT0014] Recently, it was reported that the combination of chemotherapeutics and siRNA targeting MDR genes loaded in nanomaterials can overcome MDR and kill the cancer cells.[@CIT0015]--[@CIT0019] However, the delivery of drug/gene into tumors strongly relies on the sophisticated design of drug delivery system (DDS), and drug/gene is required to be released in a controlled manner. On the other hand, the biosafety of DDS also remains a concern. Therefore, there is an urgent need for a drug delivery method that is safe, can overcome multidrug resistance, and has an optimized antitumor therapeutic efficacy.

To date, multifunctional nanoplatforms were designed for both diagnostic and therapeutic features, which have attracted great interests. Nanoparticle designed for diagnostic purposes can monitor the delivery of chemotherapeutic agents, thus it can guide the cancer therapy. Typical examples include NIRF imaging, photoacoustic (PA) imaging, ultrasound (US) imaging, magnetic resonance (MR) imaging and positron emission tomography (PET) imaging.[@CIT0020]--[@CIT0024] Although traditional delivery formulations combined therapeutic agents and imaging agents into a nanoplatform, its potential toxicity, overly complicated design, and poor drug loading capacity of nanocarriers make this type of treatment far too impractical for clinical application. To solve this issue, nanotheranostics that are achieved directly from small molecules without any carrier have attracted great attention.[@CIT0025]--[@CIT0028] Self-delivered drug is a safer method, and it could also achieve high drug loading as carriers are no longer necessary. Moreover, it is relatively easy to mass produce.[@CIT0029]--[@CIT0034] Scientists have already studied nanodrug self-delivery systems formed by two or more different drugs for combination cancer therapy.[@CIT0027] However, few reports have been reported about nano-drug previously designed by photothermal agent and chemotherapeutic drug directly for imaging-guided combination therapy, and simultaneously overcome multidrug resistance of tumors which are not sensitive to chemotherapy.

Dox, an anthracycline that can interact with DNA, is highly effective used to treat a wide variety of cancers.[@CIT0008],[@CIT0035],[@CIT0036] ICG, the common NIR organic dye for noninvasive bio-imaging and drugs for cancer PTT.[@CIT0037] Herein, we consider that Dox and ICG can self-assemble to form nanoparticles due to electrostatic, π--π stacking, or hydrophobic interactions. In addition, TPGS is a water-soluble macromolecule derived from natural vitamin E, it has been used as a safe carrier for drug delivery and widely used in nanomedicine.[@CIT0038]--[@CIT0040] Moreover, TPGS is an excellent surfactant, a good candidate that serves as an emulsifier, drug solubilizer and stabilizer. Nanoparticles with TPGS can extend blood circulation time.[@CIT0041],[@CIT0042] Furthermore, TPGS could serve as an inhibitor of P-gp to combat MDR. The P-gp inhibition mechanisms may be considered to include down-regulation expression of P-gp, inhibition of P-gp ATPase and mitochondria membrane potential decrease.[@CIT0043]--[@CIT0045] In this work, we developed a theranostic NP that is self-assembled by FDA-approved agents, allowing for fluorescence (FL) imaging-guided chemo-PTT cancer therapy and the reversal of MDR. TPGS are used for a surfactant for NPs. It improves the dispersion of drugs in water, increases cellular uptake of drugs and restores sensitivity to chemotherapeutic drugs in drug-resistant cells. A large number of Dox and ICG could be delivered themselves into tumor sites, to kill tumor cells synergistically. Thus, the NP system is a promising candidate for imaging-guided drug-resistant tumor ablation ([Figure 1](#F0001){ref-type="fig"}).Figure 1A multifunctional theranostic system, which was developed through FDA-approved self-assembling drugs, which contain anticancer drug doxorubicin (Dox), imaging and high photothermal conversion drug indocyanine green (ICG) and P-gp regulator TPGS. This novel system is a promising candidate for imaging-guided drug-resistant tumor ablation.

Materials and Methods {#S0002}
=====================

Materials {#S0002-S2001}
---------

Doxorubicin was obtained from Dalian Meilun Biotech Co., Ltd (Dalian, China). D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was purchased from Ai Keda Chemical Technology Co., Ltd (Chengdu, China). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) was obtained from Sigma Chemical Corporation (USA). Indocyanine green was obtained from Meilunbio (China). All other chemicals were of reagent grade. Water was purified with a Milli--Q Plus 185 water purification system (Millipore, Bedford, MA). Multidrug-resistant gastric cancer cell line SCG7901 was gift by the Fourth Military Medical University Chinese Academy of Sciences, and the cells were purchased commercially by them. DAPI, Calcein-AM, and propidium iodide (PI) were obtained from Invitrogen (USA). Cell lysates (RIPA) and Protease inhibitor (PMSF) were bought from Sigma Chemical Corporation (USA). P-gp antibody was obtained from Abcam. HRP-labeled goat antimouse IgG secondary antibody was got from Sunshine bio (China), and ECL kit was obtained from Promega (China).

Preparation of Dox-ICG and T/Dox-ICG NPs {#S0002-S2002}
----------------------------------------

First, Dox-ICG NPs were prepared by self-assembly technique. In brief, Dox and ICG were dissolved in 20 mL deionized water with the mass ratio of 1:1 and 1:2. Then, the mixture solution was stirred at room temperature for 12 h. After that, the product was centrifuged at 7, 000 g for 10 min, then washed by deionized water several times to remove excess Dox and ICG. After determining the appropriate ratio of two drugs, TPGS was added to Dox-ICG solution and stirred for 2 h at room temperature (mass ratio = 1:1:1). Next, an Amicon Ultra-15 centrifugal filter (MWCO 10KD, USA) was used to wash the resulting solution for three times to remove TPGS.

Characterization of Dox-ICG and T/Dox-ICG NPs {#S0002-S2003}
---------------------------------------------

The morphology of the Dox-ICG and T/Dox-ICG NPs was characterized by transmission electron microscopy (TEM, JEOL, Japan). The morphology of T/Dox-ICG NPs was also measured by scanning electron microscope (SEM, JEOL JSM-5900, Japan). The size, size distribution, and zeta potential of these nanoparticles were analyzed by an SZ-100 Nano Particle analyzer (Horiba Scientific). Ultraviolet−visible-near-infrared (UV−vis-NIR) absorbance spectra were recorded with a microplate reader (SH-1000 Lab, Japan). The Dox and ICG encapsulation efficiency were then studied by UV−vis spectrophotometer at 480 nm and 780 nm, respectively. The obtained T/Dox-ICG NPs were also observed by CLSM (Olympus, Germany). The fluorescence spectra were performed on an LS-55 luminescence spectrometer (PerkinElmer, Inc., USA; ex: 740 nm). The in vitro FL imaging and FL signals intensity of particles were obtained at 780 nm with fluorescence intensity with Carestream FX PRO ﬂuorescence imaging system. The photothermal capacity of samples was evaluated using an 808 nm NIR laser. The drug encapsulation efficiency and drug-loading content are acquired through the following formula: drug encapsulation efficiency (%) = (weight of loaded drug) / (weight of initially added drug) × 100%; drug-loading content (%) = (weight of loaded drug) / (total weight of NPs) × 100%.

In vitro Drug Release {#S0002-S2004}
---------------------

In vitro release profiles of Dox and ICG from T/Dox-ICG NPs were evaluated as follows: 2 mL solution was added to a dialysis bag (MWCO 10, 000 Da), and incubated in PBS (pH 5.5 and 7.4) at 37°C in a 50 mL centrifuge tube under horizontal shaking at 300 rpm. Then, 1 mL of the release solution was taken out and replaced with new equal volume of PBS at selected time point. The released Dox and ICG content were detected by UV−vis spectrometry at 480 nm and 780 nm, respectively. The tests were repeated three times.

Cell Culture {#S0002-S2005}
------------

Multidrug-resistant SCG 7901/VCR cells were incubated in RPMI-1640 medium supplemented with 10% FBS and 1% antibiotics at 37°C with 5% CO~2~. During the cell culture, 1 mg/mL vincristine was added to the medium to maintain the resistant phenotype.

In vitro Cellular Uptake and Intracellular Distribution of Dox {#S0002-S2006}
--------------------------------------------------------------

The cellular uptake of Dox-ICG, T/Dox-ICG NPs and intracellular Dox accumulation and retention was performed on the confocal fluorescence microscope (Nikon C2). SCG 7901/VCR cells were seeded onto cell culture dishes, after 24 hrs incubation, the cells were treated with Dox-ICG, T/Dox-ICG NPs (Dox concentration 10 μg/mL). After incubation for 12 and 24 h, the cells were washed with cold PBS for three times, and fixed by 4% paraformaldehyde for 10 min, washed with PBS thrice again, and then stained with DAPI for 10 min and washed. The dishes were further imaged under the CLSM.

Western-Blot Assay {#S0002-S2007}
------------------

The P-gp level was tested by western-blot. Cells were seeded in 10 cm plates, which containing 5\*10^6^/plate, the cells were exposed to Dox-ICG and T/Dox-ICG treatment. After 24 hrs incubation, the cells with all groups were collected and washed, then lysed in RIPA buffer (50 mM Tris--HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate, 1 mM EDTA) containing 1mM phenylmethylsulfonyl fluoride on the ice for 30 min, and got the cell lysates. Using bicinchoninic acid (BCA) method to measure total protein, protein was loaded SDS-PAGE equally, after 120v/2h, the gel was transferred onto PVDF membrane, the membrane was blocked with BSA 1 hrs and washed with twain 20 three times, then was incubated with mouse monoclonal IgG1 of P-gp at 40°C overnight. After that, the membrane was first washed three to five times, and incubated with HRP-labeled goat antimouse IgG secondary antibody at room temperature for 1 h. After washed, added color liquid, and exposed to signals were detected with the ECL kit, actin was used as an internal control.

In vitro Cytotoxicity Assay {#S0002-S2008}
---------------------------

SCG 7901/VCR cells were cultured onto 96-well plates containing 100 μL medium, to obtain a concentration of 10,000 cells per well. After overnight incubation, Dox, free ICG, Dox-ICG and T/Dox-ICG NPs were added to treat cells for 12 h at 37°C under 5% CO~2~ in the dark. Next, the cells were washed with fresh medium, and then exposed to an 808 nm laser at 1 W/cm^2^ for 5 min, followed by a further incubation of 37°C under 5% CO~2~ for 6 h. After an extra 6 h of incubation in the dark, the cell viability was evaluated by the MTT assay. For the T/Dox-ICG NPs with 808 nm laser group, the cells were seeded onto a 6-well plate and then incubated for 24 h. and treated with T/Dox-ICG NPs 12-hr incubation in the dark. The cells were replaced with fresh culture medium, irradiated with or without an NIR laser for 5 min. After further incubation for 12 h, the cells were washed with PBS three times and stained with Calcein-AM and PI.

Results and Discussions {#S0003}
=======================

Preparation and Characterization of Dox-ICG and T/Dox-ICG NPs {#S0003-S2001}
-------------------------------------------------------------

To prepare the self-delivered system with three agents for chemotherapy-resistant tumor imaging and therapy. We first explored the appropriate proportion of Dox and ICG. Dox and ICG were designed based on electrostatic interactions, π--π stacking, or hydrophobic interactions. Dox and ICG were mixed in a ratio of 1:1 and 1:2, we noted that the size of Dox-ICG NPs can be adjusted by altering the mass ratio of Dox to ICG. The transmission electron microscopy (TEM) revealed that the morphology and dispersion of ICG-Dox NPs were relatively uniform with a mass ratio of 1:1 ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}), and dynamic light scattering (DLS) data also suggested the size of Dox-ICG NPs can be adjusted by altering the mass ratio of Dox to ICG, and we found its size distributions displayed a spacious feature, which reflects the uneven morphology of the particle ([Figure 3A](#F0003){ref-type="fig"}). Ultraviolet-visible-near-infrared (UV-vis-NIR) absorption of Dox-ICG was shown in [Figure 3B](#F0003){ref-type="fig"}. Surprisingly, as the ratio of Dox to ICG increased, its absorption value decreased accordingly, which might be because a large proportion of the two drugs was not adequately nanosized. In addition, the zeta potential of Dox-ICG NPs increased from approximately −30 mV to −20.1 mV by adjusting the mass ratio of Dox to ICG ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=232449.docx)]{.ul}), suggesting there was electrostatic interactions between Dox and ICG. The emergence of multidrug resistance (MDR) remains a major hurdle in cancer chemotherapy. Various strategies including MDR modulators, multifunctional nanocarriers, and RNAi therapy, have been conducted to overcome these MDR mechanisms. The main drawback of MDR modulators is the unacceptably high toxicity that subsequently limited their clinical trials.[@CIT0014] Meanwhile, multifunctional nanocarriers and RNA interference (RNAi) therapy require a sophisticated DDS design, therefore, their application also yielded generally disappointing results. TPGS is an FDA-approved excellent emulsifier as well as drug stabilizer, and is utilized to reverse MDR. Therefore, we designed a self-assembly nanoplatform modified with TPGS. After the TPGS was added, TEM showed that the T/Dox-ICG NPs showed good monodispersity ([Figure 2C](#F0002){ref-type="fig"}), scanning electron microscopy (SEM) images also revealed the diameter of T/Dox-ICG NPs ([Figure 2D](#F0002){ref-type="fig"}). DLS showed its average diameter is about 19.03 nm, which was smaller than ICG-Dox, the results of DLS also confirmed their size distributions displayed a cramped feature, which means T/Dox-ICG NPs were more dispersed ([Figure 3A](#F0003){ref-type="fig"}). The UV-vis-NIR of the T/ICG-Dox NPs was compared to that of the ICG-Dox, and the value at 808 nm of T/ICG-Dox NPs was the highest, which for the further photothermal property study under the 808 nm laser ([Figure 3B](#F0003){ref-type="fig"}). The fluorescence spectra of Dox, ICG and T/Dox-ICG NPs are shown in [Figure 3C](#F0003){ref-type="fig"}. Confocal laser scanning microscopy (CLSM) images showed that both Dox (red color) and ICG (green color) dyes were distributed throughout the co-self-assembly NPs, and the yellow color indicated the merge of Dox and ICG ([Figure 3D](#F0003){ref-type="fig"}). More importantly, the content of Dox and ICG was measured to be \~32.56 wt% and \~25.67wt% (encapsulation efficiency of Dox and ICG was tested to be \~95.3% and \~92.4%), respectively. What's more, there is was no precipitation after incubation in water, PBS, NaCl, DMEM or FBS, suggesting that T/Dox-ICG NPs are stable and can be stored without sedimentation or aggregation ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=232449.docx)]{.ul}). This revealed the T/ICG-Dox NPs were steadfast.Figure 2(**A**) TEM images Dox-ICG (1:2), (**B**) TEM images Dox-ICG (1:1) and (**C**) TEM images T/Dox-ICG NPs (1:1:1). (**D**) SEM images of T/Dox-ICG NPs.Figure 3(**A**) DLS of the Dox-ICG (1:2), Dox-ICG (1:1) and T/Dox-ICG NPs (1:1:1). (**B**) Absorbance spectra of Dox-ICG (1:2), Dox-ICG (1:1) and T/Dox-ICG NPs (1:1:1) aqueous solutions. (**C**) The fluorescence spectra of free Dox, free ICG and T/Dox-ICG NPs. (**D**) CLSM images of Dox and ICG, red means Dox, green means ICG, yellow means the merge of Dox and ICG (Scale bar, 100 nm).

In vitro FL Imaging {#S0003-S2002}
-------------------

Because T/Dox-ICG NPs had strong NIR absorbance, we then tested and quantified their FL property. As expected, the T/Dox-ICG NPs showed more notable FL signal than Dox-ICG and free ICG ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}). An enhanced FL signals likely suggests that a greater concentration of ICG in self-assembly NPs. These results confirmed T/Dox-ICG NPs have a good potential for imaging-guided therapy.Figure 4(**A**) FL images and (**B**) FL signal intensity of free ICG, Dox-ICG and T/Dox-ICG NPs with different ICG concentrations. (**C**) Infrared thermographic images and (**D**) photothermal heating curves of free ICG, Dox-ICG and T/Dox-ICG NPs under 808 nm laser irradiation (1 W/cm^2^, 5 min).

In vitro Photothermal Effect {#S0003-S2003}
----------------------------

To investigate the photothermal conversion efficiency of T/Dox-ICG NPs. In our experiment, the temperature changes of free ICG, Dox-ICG, and T/Dox-ICG NPs solutions upon NIR laser irradiation (808 nm, 1 W/cm^2^) were evaluated at different times. As shown in [Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}, as the irradiation time increased, the temperatures of T/Dox-ICG NPs increased accordingly. After 5 min laser irradiation, the temperature of free ICG, Dox-ICG, and T/Dox-ICG NPs reached 39.82, 43.83 and 56.96°C, respectively, indicating that free ICG has poor photostability. In addition, the Dox-ICG showed a higher temperature than free ICG, which suggests a higher concentration of ICG within Dox-ICG was formed by Dox and ICG. The results demonstrated the enhanced PTT effect of T/Dox-ICG NPs.

In vitro Dox and ICG Release {#S0003-S2004}
----------------------------

In vitro Dox and ICG release profiles were evaluated by dialysis in PBS at pH 7.4, and 5.4 at 37°C, respectively. As the results in [Figure 5](#F0005){ref-type="fig"}, the releasing of T/Dox-ICG NPs was based on different pH conditions. Both Dox and ICG showed burst release at first both in the normal physiological pH (pH 7.4) and acidic condition (pH 5.4). However, it was followed by a controlled releasing phase, in which the Dox and ICG showed a slow release at pH 7.4 after 12 h, and only about 36.87% of Dox and 39.65% of ICG were released over 24 h. Nevertheless, in the next 48 h, the cumulative release of Dox and ICG was increased to 88.76% and 79.83% at acidic pH 5.4, respectively. The result could be ascribed to the protonation of Dox in an acidic environment, thus the hydrophobic interaction between Dox and ICG was weakened. The results revealed T/Dox-ICG NPs might have lower toxicity in normal tissue during anticancer treatment.Figure 5Cumulative release of Dox and ICG from T/Dox-ICG NPs at pH 7.4 and 5.5.

Western-Blot Assay {#S0003-S2005}
------------------

The MDR occurs mainly include overexpressed MDR protein P-gp, which can reduce intracellular drug concentration and mediate MDR. TPGS has been found to inhibit P-gp and reverse MDR. A Western blot assay was performed to analyze P-gp expression levels in SCG7901/VCR cells after incubation with T/Dox-ICG NPs ([Figure 6A](#F0006){ref-type="fig"}). The control and Dox-ICG showed no obvious inhibition of P-gp expression. However, it was found that T/Dox-ICG NPs exhibited significant inhibition of P-gp expression. The relevant P-gp expression was calculated by the signal intensity of the protein bands ([Figure 6B](#F0006){ref-type="fig"}). The results suggest that the effective cytotoxicity activity of T/Dox-ICG NPs maybe attributed to TPGS-mediated P-gp inhibition.Figure 6(**A**) Detection of P-gp knockdown in SCG7901/VCR cells by T/Dox-ICG using Western blot and (**B**) the relevant P-gp expression was calculated by the signal intensity of the protein bands.

In vitro Cellular Uptake and Intracellular Distribution of Dox {#S0003-S2006}
--------------------------------------------------------------

To investigate the cellular internalization of Dox, SCG 7901/VCR cells were incubated with Dox-ICG and T/Dox-ICG NPs and then assessed by CLSM. As shown in [Figure 7A](#F0007){ref-type="fig"}, at 12 h, the cellular uptake of Dox-ICG group, the red fluorescence of Dox was mainly localized in cytoplasm, whereas T/Dox-ICG NPs were transported into nucleus at the same time. It should be noted that after 24 h, the red fluorescence of Dox moved into the nucleus in the SCG 7901/VCR cells. The qualitative result of Image J analysis confirmed a significant amount of Dox in the nucleus of the SCG 7901/VCR cells ([Figure 7B](#F0007){ref-type="fig"}). Meanwhile, free DOX was efficiently exported by overexpressing P-gp; thus, the amount of intracellular DOX was rapidly eliminated ([[Figure S3](https://www.dovepress.com/get_supplementary_file.php?f=232449.docx)]{.ul}). This means without TPGS, the entry of Dox into the nucleus was inhibited in SCG 7901/VCR cells, but with the aid of TPGS, the enrichment of Dox inside the nucleus was facilitated. Along this line of thinking, TPGS might affect mitochondrial structure and function, thereby reversing tumor resistance.Figure 7(**A**) CLAM of Dox-ICG and T/Dox-ICG NPs incubation with SCG7901/VCR cells for different times (Scale bar, 50 μm). Merged images display the overlay of red autofluorescence of Dox and green fluorescence of ICG. (**B**) Nuclear uptake of DOX bySCG7901/VCR cells. (**C**) Fluorescence images of calcein AM/PI stained SCG7901/VCR cells after T/Dox-ICG NPs treatments with or without laser irradiation (Scale bar, 20 μm). (**D**) Cell viability of SCG7901/VCR cells after various treatments for 24 h.

In vitro Chemotherapy, PTT, and Chemo-PTT Treatments {#S0003-S2007}
----------------------------------------------------

The cytotoxicity of different materials against SCG 7901/VCR cells was evaluated by the MTT assay. SCG 7901/VCR cells were incubated with ICG, ICG +laser (808 nm laser irradiation 1W/cm^2^, 5 min), Dox, Dox-ICG, T/Dox-ICG NPs, T/Dox-ICG NPs +laser (808 nm laser irradiation,1W/cm^2^, 5 min), respectively. The T/Dox-ICG NPs +laser group showed much more cytotoxicity with the cell killing efficacy was reach to \~91.25%. And with free ICG, the cells showed greater survival rate. The T/Dox-ICG NPs group showed higher cytotoxicity than free Dox and Dox-ICG, which could be interpreted by an enhanced cellular uptake, and cells are more sensitive to Dox after TPGS inhibited the expression of P-gp ([Figure 7D](#F0007){ref-type="fig"}). This result was also examined by the co-staining assay. Cells were stained with calcein-AM and PI, in which dead cells were stained by PI (red fluorescence) and live cells were stained by calcein-AM (green fluorescence). In the control, there was no red fluorescence, but the T/Dox-ICG NPs +laser treated cells showed significant difference with red fluorescence signals ([Figure 7C](#F0007){ref-type="fig"}). All the results revealed that T/Dox-ICG NPs NPs had enhanced effect in Dox delivery and chemo-PTT treatment.

Conclusion {#S0004}
==========

In summary, we successfully synthesized a novel multifunctional T/Dox-ICG NPs for imaging-guided chemo-PTT combination therapy and overcome MDR. T/Dox-ICG NPs displayed ample stability in water, good monodispersity, higher drug-loading efficiency and excellent drug-releasing profile in tumor environment. T/Dox-ICG NPs showed enhanced FL imaging and high photothermal conversion properties. The FL intensity of T/Dox-ICG NPs was 5.53 times and the temperature of T/Dox-ICG NPs was 17.14°C higher than free ICG. Compared with Dox-ICG, the T/Dox-ICG NPs exhibited more significant nuclear localization of Dox in SCG7901/MDR cells, as TPGS had an evident effect on the inhibition of P-gp. T/Dox-ICG NPs with laser can induce higher cytotoxicity on MDR cells compared with other groups, its cell survival was only 8.75%. Taken together, T/Dox-ICG NPs provide a promising carrier for imaging-guided combination therapy, and further overcome P-gp mediated MDR to improve anticancer effect.
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